SAN DIEGO, September 20, 2016 /PRNewswire/ --
Regen BioPharma Inc. (OTCQB: RGBP), (OTCQB: RGBPP) today announced completion of experiments demonstrating immunological effects of its novel NR2F6 small molecule modulators. These experiments were conducted in collaboration with Dr. Xiaojing Ma, Professor of Microbiology and Immunology at Weill Cornell Medical College.
The experiments revealed that administration of Regen’s proprietary compounds RG-NA01, RG-NI01 and RG-NI02 prevented cells of the immune system from producing the inflammatory factors interleukin-2, interferon-gamma, tumor necrosis factor-alpha and, importantly, interleukin-17a. These factors are critically involved in the immune response found in autoimmune diseases such as rheumatoid arthritis and psoriasis.
The company is currently developing small molecule drugs that target NR2F6 and either inhibit production of these factors or, in other cases, stimulate their production. The goal is to have a series of compounds that can modulate the immune system up or down.
Regen has recently filed a composition of matter patent application covering these novel NR2F6 small molecule modulators. NR2F6 is a molecular switch which controls genes associated with the immune response.
“We are delighted to discover that our lead compounds have a cellular effect, even though these compounds are not optimized yet,” said Harry M. Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen. “These preclinical experiments firmly support our initial screening data which discovered these compounds. Now, it is a matter of optimizing these compounds to improve their efficacy. To date, no one in the world has reported the discovery of molecules, natural or synthetic, which activate or inhibit NR2F6 except Regen.”
“The significance of these preclinical studies is that the data support our belief that controlling NR2F6 is key in treating autoimmune diseases such as arthritis by activating NR2F6. Additionally, the data suggest that by inhibiting NR2F6, these compounds can be used to treat cancer. In lay terms, if we turn the “light switch” on it causes NR2F6 to suppress the immune system thus potentially allowing treatment of rheumatoid arthritis and other autoimmune diseases. If we turn off the “light switch” we can cause the immune cells to be activated and kill cancer cells,” stated David Koos, PhD, Chairman and CEO of Regen BioPharma Inc. “There are miles to go before we are finished but, these series of studies with Dr. Xiaojing Ma are very important. Regen believes we are on the verge of something extremely powerful in treating both autoimmunity and cancer.”
About Regen BioPharma Inc.:
Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is focused on gene silencing therapy and small molecule therapies for treating cancer, along with developing stem cell treatments for aplastic anemia and disorders of the bone marrow. Additional information on Regen BioPharma is available at http://www.regenbiopharmainc.com.
Disclaimer: This news announcement may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.
CONTACT INFORMATION
Regen BioPharma Inc.
David R. Koos, Ph.D.
Chairman & Chief Executive Officer
+1-619-702-1404 Phone
+1-619-330-2328 Fax
SOURCE Regen BioPharma, Inc.
